The development of drug resistance is a major problem in effective chemotherapy of cancer. During the past few years, the phenomenon of multidrug resistance (MDR) has been described (Ling et al., 1983; Volm et al., 1987) . Frequently, MDR-cells overexpress a membrane protein (P-glycoprotein, P-170) which is thought to function as an efflux pump for different cytostatics and thereby cause the development of drug resistance (Juliano & Ling, 1976; Chen et al., 1986 (Bech-Hansen et al., 1976) . The detection of P-glycoprotein by Western blotting was carried out as described previously (Volm et al., 1989 (Medac) was dialysed against 2 litres of cold acetate buffered saline for 60 min. Thereafter, ml of 265/F4-SPDP (1 mg) was applied to 3.5 ml RAC (0.7 mg). The mixture was immediately dialysed against 1 litre of phosphate buffered saline (pH 7.8) for 16-20 h at room temperature. The 265/F4-RAC conjugates were separated from uncoupled RAC by gel filtration on a 1 cm x 50 cm Sephacryl S-200 column (Pharmacia, Freiburg, Germany), equilibrated with PBS (pH 7.0) and subsequently sterile filtered.
ml-') and 265/F4-RAC immunotoxin (31ig ml-'), respective- ly, were applied for 20 h at 4°C. Then, three rinsing steps with phosphate buffered saline (PBS, pH 7.4) Table I , there are no differences in the reactivity between the immunotoxin and the native antibody. In control measurements, the anti-RAC antibody failed to detect uncoupled 265/F4 indicating the specificity of the radioimmuno-reaction.
In order to examine whether MAb 265/F4 possesses an inhibitory effect on cell growth, we exposed sensitive and resistant CHO-cells to different concentrations of this antibody in drug-free medium. As can be seen in Figure 2a , Figure 2b . Again, the growth of resistant cells could be inhibited selectivity dependent on the concentration of 265/ F4-RAC conjugate. At a concentration of 3 gig ml ' cell growth was reduced by 90%. In contrast, the same concentration of immunotoxin caused only a growth inhibition of 10% in sensitive cells. In control experiments an inhibitory effect of uncoupled ricin alpha chain was not observed (data not shown).
Furthermore, we analysed the effect of MAb MRK 16 which detects P-glycoprotein in human cells, but not in CHO cells on cell growth of sensitive and resistant CHO-cells. In this experiment we proved whether a specific targetting of Doses (,ug ml -') P-glycoprotein is required to inhibit cell growth or whether increased unspecific membrane turnover and protein internalisation in resistant cells result growth inhibition. As can be seen in Figure 3 , MAb MRK 16 had only marginal effect on cell growth of both sensitive and resistant CHO cells. a Thus far, several monoclonal antibodies (265/F4 (Lathan et al., 1985) ; C219, C494 (Kartner et al., 1985) , 32G7 (Danks et al., 1985) , MRK 16, MRK 17 (Hamada & Tsuruo, 1986) , JSB-1 (Scheper et al., 1988) , HYB-612 (Meyers et al., 1989) , and polyclonal antibodies P7 (Richert et al., 1988) , anti-P, anti-C (Yoshimura et al., 1989) , anti-PO, anti-P4, 4007, 4077 (Bruggemann et al., 1989) ) against P-glycoprotein has been prepared. However, only few of these antibodies (265/F4, MRK 16, MRK17, and HYB-612) were developed against intact tumour cells and recognised external epitopes of Pglycoprotein. The external targetting of surface proteins by monoclonal antibodies can be used for immunotherapeutical approaches. Therefore, antibodies recognising external epitopes of P-glycoprotein might be suitable for an efficaceous treatment of MDR-cells. Indeed, our results and the experiments of Hamada and Tsuruo (1986) indicate that the antibodies 265/F4, MRK 16 and MRK 17 possess biological activity against MDR-cells in vitro. Both MRK 16 and MRK 17 have been used for the selective growth inhibition of human MDR-tumours in nude mice (Tsuruo et al., 1989) . In contrast to the growth inhibitory feature of 265/F4, application of this antibody to drug-containing medium showed that 265/F4 is unable to modulate drug accumulation (unpublished results). The biochemical mechanism of the selective growth-inhibitory effect of MAb 265/F4 on multidrug-resistant CHO-cells is until now unclear. We found a marginal inhibition effect of MAb 265/F4 on sensitive CHO-cells. MAb MRK 16 which does not cross-react with P-glycoprotein of CHO-cells also inhibited growth of sensitive and resistant cells to a small extent. We suggest that these marginal effects were not due to binding of P-glycoprotein. was also observed at lower concentrations (1 lgml-', Hamada & Tsuruo, 1986 ) as compared to uncoupled 265/F4 (10-I00 ig ml-'). This might reflect differences in the binding affinities of the two antibodies to P-glycoprotein. The selective growth inhibition by MAb 265/F4 and 265/F4-RAC immunotoxin in vitro raises the possibility. of using this antibody for the treatment of human tumours which are unresponsive to conventional therapy by doxorubicin or vincristine. However, before such immunotoxicological approaches for the treatment of MDR-cells can be established, several problems remain to be solved. One substantial obstacle is the expression of P-glycoprotein in certain normal tissues, e.g. kidney, liver, colon and brain capillaries (Sugawara et al., 1988) . Nevertheless, the selective killing of MDR-cells by 265/F4 should encourage further investigation which may provide guidelines for the improvement of conventional chemotherapy.
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